Agenus Appoints Robert B. Stein, MD, PhD, as Chief Scientific Officer
January 13 2014 - 7:00AM
Business Wire
Agenus Inc. (NASDAQ: AGEN), a biotechnology company developing
novel immune system activating treatments for cancers and
infectious diseases, today announced the appointment of Robert B.
Stein, M.D., Ph.D., to the newly-created position of Chief
Scientific Officer (CSO).
Dr. Stein will lead Agenus’ Research, Pre-clinical Development
and Translational Medicine functions and guide the company’s
clinical development. In addition, pending closing, Dr. Stein will
play a critical role in leading the integration of the 4-Antibody
acquisition announced today, which includes the company’s fully
human antibody drug discovery and optimization technology platform
and portfolio of immune checkpoint antibody programs.
“Dr. Stein brings over 30 years of experience and
accomplishments to the Agenus leadership team. He is an innovative
and experienced executive with deep, broad knowledge of biology,
medicine and pharmaceutical science,” said Garo Armen, PhD, CEO and
chairman of Agenus. “Dr. Stein has had a terrific record in
identifying and developing novel therapeutic modalities. He will
play a key strategic role as we expand into the immune checkpoint
field and in our efforts to establish Agenus as a leader in
immuno-oncology. We are delighted to have him on board.”
“It is now evident that the immune system plays a powerful role
in controlling cancer. Agenus’ roots in immunotherapy combined with
4-Antibody’s state-of-the-art human monoclonal antibody platform
and established immune checkpoint programs provide a broad spectrum
of immunological approaches to combat cancers and other major
diseases,” said Robert Stein, MD, PhD, CSO of Agenus.
“Collaborations with the Ludwig Cancer Research Institute and
Memorial Sloan Kettering Cancer Center provide tremendous
advantages in discovering and developing immune-based medicines for
patients battling cancer. I am very excited to join Agenus during
this transformational time.”
Over the course of Dr. Stein’s career he’s played a key role in
bringing eight drugs to the market. He has held a number of
progressively responsible senior management positions including CSO
& SVP of Research for Ligand Pharmaceuticals, EVP of Research
& Pre-clinical Development for Dupont Merck, President and CSO
for Incyte Pharmaceuticals, President of Roche Palo Alto and CEO of
KineMed. Dr. Stein spent the early part of his career at Merck,
Sharp and Dohme Research Laboratories. He holds an MD and a PhD in
Physiology & Pharmacology from Duke University.
About Agenus
Agenus Inc. is a biotechnology company developing treatments for
cancers and infectious diseases. The company has multiple
immunotherapeutic products based on strong technology platforms
that are advancing through the clinic. Agenus’ technology is
further validated through partnerships with major pharmaceutical
companies, with several product candidates in late-stage clinical
trials with corporate partners. Between Agenus and its partners, 23
programs are in clinical development. For more information, please
visit www.agenusbio.com, or connect with the company on Facebook,
LinkedIn, Twitter and Google+.
Forward-Looking Statement
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission for the
period ended September 30, 2013. Agenus cautions investors not to
place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this document, and Agenus undertakes no obligation to
update or revise the statements. All forward-looking statements are
expressly qualified in their entirety by this cautionary statement.
Agenus’ business is subject to substantial risks and uncertainties,
including those identified above. When evaluating Agenus’ business
and securities, investors should give careful consideration to
these risks and uncertainties.
Agenus Inc.Jonae R. Barnes, 617-818-2985Vice PresidentInvestor
Relations and Corporate
Communicationsjonae.barnes@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024